생명과학 BPO 시장 규모, 점유율 및 동향 분석 보고서 : 서비스별, 지역별, 부문별 동향(2023-2030년)

Life Sciences BPO Market Size, Share & Trends Analysis Report By Services (Pharmaceutical Outsourcing, Medical Devices Outsourcing, Contract Sales And Marketing Outsourcing, Others), By Region, And Segment Forecasts, 2023 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

생명과학 BPO 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 생명과학 BPO 시장 규모는 2030년까지 8,275억 달러에 달할 것으로 예상되며, 예측 기간 동안 9.3%의 CAGR을 나타낼 것으로 예상됩니다.

의약품 개발, 전임상시험, 임상시험, 시판 후 조사 비용 상승, 특허 절벽 상승, 제품 파이프라인 증가, 규제 제약 등이 시장을 주도하는 주요 요인입니다. 제약 및 생명공학 산업은 새로운 분자, 기기 및 치료법을 지속적으로 도입하기 위해 R&D 부문에 많은 투자를 하고 있습니다. 신약 개발, 전임상시험, 임상시험과 같은 의약품 개발의 여러 단계에는 막대한 자금, 기술 및 인적 자원이 필요합니다.

아웃소싱 공급업체들은 업계 증가하는 수요에 대응하기 위해 제품 및 서비스 제공을 확대하고, 장기적인 성장과 수익성을 위해 틈새 시장을 공략하고 있습니다. 이러한 추세를 종합해 볼 때, 생명과학 분야 아웃소싱 시장은 예측 기간 동안 확대될 것으로 예상되며, 코로나19 팬데믹 기간 동안 많은 아웃소싱 업체들이 코로나19 백신과 진단에 대한 수요 증가에 대응하기 위해 기존 제조 및 연구시설을 확장했습니다. 확장했습니다. 팬데믹 이후에도 CDMO들은 미래의 의약품 수요를 지원하기 위해 유사한 전략을 실행하고 있습니다. 예를 들어, 아에노바 그룹은 2022년 4월에 1,000만 유로를 투자하여 고활성 의약품을 생산할 수 있는 새로운 시설을 개발했습니다.

시장 관계자들이 이러한 전략을 채택하는 것은 시장에 도움이 될 것으로 예상됩니다. 의약품 및 의료기기의 제조 및 개발 비용 절감에 대한 수요가 증가하고 있습니다. 제조, 연구 및 마케팅 서비스 아웃소싱은 제약 및 의료기기 기업에 비용과 시간을 절약할 수 있는 이점을 제공합니다. 이는 시장에 긍정적인 영향을 미칠 것으로 예상됩니다. 최근 몇 년동안 CRO와 CDMO의 인수합병이 증가하고 있습니다. 임상 서비스에 대한 수요 증가와 핵심 역량에 대한 집중도를 높이기 위해 전문 서비스 제공업체에 대한 수요 증가는 M&A 거래의 발생을 촉진할 것으로 예상되는 요인 중 일부입니다.

생명과학 BPO 시장 보고서 하이라이트

• 인수합병(M&A) 프로젝트 증가로 인해 CRO와 CDMO의 세계 진출이 확대되고 있으며, 엔드 투 엔드 서비스를 제공할 수 있는 능력이 향상되고 있습니다. 이러한 추세의 지속은 시장에 큰 이익을 가져다 줄 것으로 예상됩니다.
• 코로나19 발병률은 세계 백신 접종 캠페인의 확대로 인해 크게 감소하고 있습니다.
• 이러한 이유로 CRO와 CDMO는 현재 부담이 큰 암 및 기타 질병에 대한 치료제 개발에 집중하고 있습니다.
• 예를 들어, 2022년 4월, 랩코프는 엑스셀 바이오사이언스(Xcell Biosciences)와 제휴하여 암, 파킨슨병 및 기타 희귀질환을 치료할 수 있는 세포 및 유전자 치료제를 개발할 수 있도록 지원할 예정입니다.
• 암 및 기타 희귀질환 치료에 있어 유전자 치료의 높은 효과로 인해 CDMO의 이러한 이니셔티브는 시장에 이익을 가져다 줄 가능성이 높습니다.
• 의료기기 분야는 의료기기 설계와 관련된 복잡성으로 인해 2023년부터 2030년까지 가장 빠른 CAGR을 기록할 것으로 예상됩니다.
• 세계적으로 의료기기 승인에 대한 엄격한 규제 프레임워크는 의료기기 아웃소싱 서비스에 대한 수요를 더욱 증가시키고 있습니다.
• 아태지역은 비용 효율적인 BPO 서비스를 제공하는 많은 CRO가 존재하기 때문에 2022년에 가장 큰 매출 점유율을 차지할 것으로 예상됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 생명과학 BPO 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 보급과 성장 전망 매핑
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 생명과학 BPO 시장 분석 툴
  • 업계 분석 - Porter의 Five Forces 분석
  • PESTEL 분석

제4장 생명과학 BPO : 서비스별 추정·동향 분석

• 생명과학 BPO 시장 : 중요 포인트
• 생명과학 BPO 시장 : 동향과 시장 점유율 분석, 2022년 및 2030년
• 의약품 아웃소싱
  • 수탁제조 시장
  • 수탁 연구기관
• 의료기기 아웃소싱
  • 수탁 제조 아웃소싱
  • 수탁 연구기관
• 계약 판매 및 마켓 아웃소싱
• 기타

제5장 생명과학 BPO 시장 : 지역별 추정·동향 분석

• 지역별 전망
• 지역별 생명과학 BPO 시장 : 중요 포인트
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제6장 경쟁 구도

• 주요 시장 진출기업의 최근 동향과 영향 분석
• 시장 진출기업 분류
  • Atos SE
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc
  • Labcorp Drug Development
  • Genpact
  • ICON plc
  • Infosys Limited
  • IBM
  • Lonza
  • Parexel
  • IQVIA Inc

LSH

영문 목차

영문목차

Life Sciences BPO Market Growth & Trends:

The global life sciences BPO market size is expected to reach USD 827.5 billion by 2030, registering a CAGR of 9.3% over the forecast years, according to a new report by Grand View Research, Inc.. The rising costs of drug development; pre-clinical and clinical trials; and post-marketing surveillance; a rise in the patent cliff; a growing product pipeline; and regulatory constraints are some of the major factors driving the market. The pharmaceutical and biotech industries invest heavily in the R&D sector to continuously introduce new molecules, devices, and treatments. The different stages of drug development, such as drug discovery, pre-clinical studies, and clinical trials, require huge financial, technological, and human resources.

To cater to the growing needs of the industry, the outsourcing vendors are expanding their product and service offerings and they are targeting niche areas for long-term growth and profitability. Altogether, these trends are expected to boost the life sciences outsourcing market over the forecast period. During the COVID-19 pandemic, a significant number of outsourcing providers expanded their existing manufacturing and research facilities to meet the growing demand for COVID-19 vaccines and diagnostics. Even post-pandemic, CDMOs are practicing similar strategies to support the future demand for pharmaceuticals. For instance, in April 2022, Aenova Group developed a new facility for manufacturing highly potent drugs with an investment of EUR 10 million.

The adoption of such strategies by the market players is expected to be profitable for the market. There has been a rising demand to reduce the cost of manufacturing and development of drugs and medical devices. Outsourcing manufacturing, research, and marketing services provide pharmaceutical and medical device companies with cost- and time-saving benefits. This is expected to have a positive impact on the market. Over the years, mergers and acquisition deals between CROs and CDMOs have increased. The rising demand for clinical services and the growing need for specialized service providers to improve the focus on their core competencies are some of the factors that are expected to drive the incidence of M&A deals.

Life Sciences BPOMarket Report Highlights:

• The increasing number of M&A transactions has broadened the global reach and improved the capabilities of CROs and CDMOs to provide end-to-end services; a continuation of this trend is expected to benefit the market significantly
• COVID-19 incidence has decreased significantly as a result of a growing global vaccination campaign
• Owing to this, the CRO and CDMO are now refocusing on developing drugs for oncology and other diseases owing to their high burden
• For instance, in April 2022, Labcorp collaborated with Xcell Biosciences to support the company in developing cell and gene therapies for treating cancer, Parkinson's, and other rare diseases
• Such initiatives by the CDMOs are likely to profit the market owing to the high effectiveness of gene therapy in treating cancer and other rare diseases
• The medical device segment is expected to register the fastest CAGR from 2023 to 2030 due to the complexities associated with medical device designing
• The strict regulatory framework for medical device approval globally has further contributed to the demand for medical device outsourcing services
• Asia Pacific held the largest revenue share in 2022 due to the presence of a significant number of CROs providing cost-effective BPO services

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Services
  • 1.1.2. Regional scope
  • 1.1.3. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Services outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Life Sciences BPO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
  • 3.3.2. Market Restraint Analysis
• 3.4. Life Sciences BPO Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic Landscape

Chapter 4. Life Sciences BPO: Service Estimates & Trend Analysis

• 4.1. Life Sciences BPO Market: Key Takeaways
• 4.2. Life Sciences BPO Market: Movement & Market Share Analysis, 2022 & 2030
• 4.3. Pharmaceutical Outsourcing
  • 4.3.1. Pharmaceutical outsourcing market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 4.3.2. Contract manufacturing market
    • 4.3.2.1. Contract manufacturing market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.2.2. API
    • 4.3.2.2.1. API estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.2.3. Finished dose form
    • 4.3.2.3.1. Finished dose form estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.2.4. Packaging
    • 4.3.2.4.1. Packaging estimates and forecasts, 2018 to 2030 (USD Billion)
  • 4.3.3. Contract research organizations
    • 4.3.3.1. Contract research Organizations estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.3.2. Drug discovery
    • 4.3.3.2.1. Drug discovery estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.3.3. Preclinical studies
    • 4.3.3.3.1. Preclinical studies estimate and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.3.4. Clinical Trial Studies
    • 4.3.3.4.1. Clinical trial studies estimate and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.3.5. Regulatory services
    • 4.3.3.5.1. Regulatory services estimate and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.3.6. Pharmacovigilance
    • 4.3.3.6.1. Pharmacovigilance estimates and forecasts, 2018 to 2030 (USD Billion)
• 4.4. Medical Devices Outsourcing
  • 4.4.1. Medical devices outsourcing market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 4.4.2. Contract manufacturing outsourcing
    • 4.4.2.1. Contract manufacturing outsourcing estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.4.2.2. Electronic manufacturing services
    • 4.4.2.2.1. Electronic manufacturing services estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.4.2.3. Finished goods
    • 4.4.2.3.1. Finished goods estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.4.2.4. Raw materials/components
    • 4.4.2.4.1. Raw materials/components estimate and forecasts, 2018 to 2030 (USD Billion)
  • 4.4.3. Contract research organizations
    • 4.4.3.1. Contract research Organizations estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.4.3.2. Regulatory consulting services
    • 4.4.3.2.1. Regulatory consulting services estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.4.3.3. Product design and development services
    • 4.4.3.3.1. Product design and development services estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.4.3.4. Product testing services
    • 4.4.3.4.1. Product testing services estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.4.3.5. Product implementation services
    • 4.4.3.5.1. Product implementation services estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.4.3.6. Product upgrade services
    • 4.4.3.6.1. Product upgrade services estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.4.3.7. Product maintenance services
    • 4.4.3.7.1. Product maintenance services estimates and forecasts, 2018 to 2030 (USD Billion)
• 4.5. Contract Sales & Market Outsourcing
  • 4.5.1. Contract sales & market outsourcing market estimates and forecasts, 2018 to 2030 (USD Billion)
• 4.6. Others
  • 4.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 5. Life Sciences BPO Market: Regional Estimates & Trend Analysis

• 5.1. Regional Outlook
• 5.2. Life Sciences BPO Market by Region: Key Takeaways
• 5.3. North America
  • 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.3.2. U.S.
    • 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.3.3. Canada
    • 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
• 5.4. Europe
  • 5.4.1. UK
    • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.4.2. Germany
    • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.4.3. France
    • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.4.4. Italy
    • 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.4.5. Spain
    • 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.4.6. Sweden
    • 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.4.7. Norway
    • 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.4.8. Denmark
    • 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
• 5.5. Asia Pacific
  • 5.5.1. Japan
    • 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.5.2. China
    • 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.5.3. India
    • 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.5.4. Australia
    • 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.5.5. Thailand
    • 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.5.6. South Korea
    • 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
• 5.6. Latin America
  • 5.6.1. Brazil
    • 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.6.2. Mexico
    • 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.6.3. Argentina
    • 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
• 5.7. MEA
  • 5.7.1. Saudi Arabia
    • 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.7.2. South Africa
    • 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.7.3. UAE
    • 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.7.4. Kuwait
    • 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Market Participants
• 6.2. Market Participant Categorization
  • 6.2.1. Atos SE
    • 6.2.1.1. Company overview
    • 6.2.1.2. Financial performance
    • 6.2.1.3. Product benchmarking
    • 6.2.1.4. Strategic Initiatives
  • 6.2.2. Boehringer Ingelheim International GmbH
    • 6.2.2.1. Company overview
    • 6.2.2.2. Financial performance
    • 6.2.2.3. Product benchmarking
    • 6.2.2.4. Strategic initiatives
  • 6.2.3. Catalent, Inc
    • 6.2.3.1. Company overview
    • 6.2.3.2. Financial performance
    • 6.2.3.3. Product benchmarking
    • 6.2.3.4. Strategic initiatives
  • 6.2.4. Labcorp Drug Development
    • 6.2.4.1. Company overview
    • 6.2.4.2. Financial performance
    • 6.2.4.3. Product benchmarking
    • 6.2.4.4. Strategic initiatives
  • 6.2.5. Genpact
    • 6.2.5.1. Company overview
    • 6.2.5.2. Financial performance
    • 6.2.5.3. Product benchmarking
    • 6.2.5.4. Strategic initiatives
  • 6.2.6. ICON plc
    • 6.2.6.1. Company overview
    • 6.2.6.2. Financial performance
    • 6.2.6.3. Product benchmarking
    • 6.2.6.4. Strategic initiatives
  • 6.2.7. Infosys Limited
    • 6.2.7.1. Company overview
    • 6.2.7.2. Financial performance
    • 6.2.7.3. Product benchmarking
    • 6.2.7.4. Strategic initiatives
  • 6.2.8. IBM
    • 6.2.8.1. Company overview
    • 6.2.8.2. Financial performance
    • 6.2.8.3. Product benchmarking
    • 6.2.8.4. Strategic initiatives
  • 6.2.9. Lonza
    • 6.2.9.1. Company overview
    • 6.2.9.2. Financial performance
    • 6.2.9.3. Product benchmarking
    • 6.2.9.4. Strategic initiatives
  • 6.2.10. Parexel
    • 6.2.10.1. Company overview
    • 6.2.10.2. Financial performance
    • 6.2.10.3. Product benchmarking
    • 6.2.10.4. Strategic initiatives
  • 6.2.11. IQVIA Inc
    • 6.2.11.1. Company overview
    • 6.2.11.2. Financial performance
    • 6.2.11.3. Product benchmarking
    • 6.2.11.4. Strategic initiatives

관련자료